Cyclins and cyclin-dependent protein kinases (CDKs) are important proteins that are
required for the regulation and expression of the large number of components necessary for …

Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Multiple myeloma is a treatable, but currently incurable, hematological malignancy of
plasma cells characterized by diverse and complex tumor genetics for which precision …

Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal
proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity …

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …

Understanding the profile of oncogene and tumor suppressor gene mutations with their
interactions and impact on the prognosis of multiple myeloma (MM) can improve the …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why
inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells …